{
    "root": "140fd496-8808-49e6-8ee2-4073befe59d9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gabapentin",
    "value": "20250501",
    "ingredients": [
        {
            "name": "GABAPENTIN",
            "code": "6CW7F3G59X"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLOXAMER 407",
            "code": "TUF2IVW3M2"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "Gabapentin tablets are indicated for: Postherpetic neuralgia in adults ( 1 ) Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )",
    "contraindications": "Postherpetic Neuralgia      ( 2.1 ) Dose can be      titrated up as needed to a dose of 1800 mg/day Day 1: Single      300 mg dose Day 2: 600      mg/day (i.e., 300 mg two times a day) Day 3: 900      mg/day (i.e., 300 mg three times a day) Epilepsy with      Partial Onset Seizures ( 2.2 ) Patients 12      years of age and older: starting dose is 300 mg three times daily; may be      titrated up to 600 mg three times daily Patients 3 to      11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three      divided doses; recommended dose in patients 3 to 4 years of age is 40      mg/kg/day, given in three divided doses; the recommended dose in patients      5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses.      The recommended dose is reached by upward titration over a period of      approximately 3 days Dose should be      adjusted in patients with reduced renal function      ( 2.3 , 2.4 )",
    "warningsAndPrecautions": "Gabapentin Tablets USP, 600 mg are white to off-white having mottled spots, oval-shaped, biconvex, film-coated tablets debossed with 'ZE72' with bisect on one side and plain with bisect on other side and are supplied as follows:\n                  NDC 68382-204-01 in bottle of 100 tablets with child-resistant closure\n                  NDC 68382-204-05 in bottle of 500 tablets\n                  NDC 68382-204-10 in bottle of 1,000 tablets\n                  Gabapentin Tablets USP, 800 mg are white to off-white having mottled spots, oval-shaped, bevelled-edge, biconvex, film-coated tablets debossed with 'ZE71' with bisect on one side and plain with bisect on other side and are supplied as follows:\n                  NDC 68382-205-01 in bottle of 100 tablets with child-resistant closure\n                  NDC 68382-205-05 in bottle of 500 tablets\n                  NDC 68382-205-10 in bottle of 1,000 tablets\n                  NDC 68382-205-77 in unit-dose blister cartons of 100 (10 x 10) unit dose tablets\n                  Store at 20째C to 25째C (68째F to 77째F) [See USP Controlled Room Temperature]. \n                  Dispense in a tight container.",
    "adverseReactions": "Known hypersensitivity to gabapentin or its ingredients ( 4 )"
}